N-desmethyl Imatinib is a major active metabolite of imatinib (Item No.
13139), an anticancer agent that selectively targets tyrosine kinases, including Bcr-ABL, platelet-derived growth factor receptor (PDGFR), and KIT.
1,2 N-desmethyl Imatinib is formed when imatinib undergoes demethylation by the cytochrome P450 (CYP) isomer CYP3A4.
3 N-desmethyl Imatinib has the same
in vitro potency at Bcr-ABL kinase as imatinib (IC
50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib, indicating the majority of the anticancer activity can be attributed to the parent compound.